SAB Biotherapeutics (SABS) Accumulated Expenses (2020 - 2026)

SAB Biotherapeutics (SABS) has 7 years of Accumulated Expenses data on file, last reported at $5.4 million in Q1 2026.

• Quarterly Accumulated Expenses rose 34.58% year-over-year to $5.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.4 million (up 34.58% YoY) and the FY2025 annual result came in at $6.6 million, up 20.3% from the prior year.
• Accumulated Expenses retreated to $5.4 million in Q1 2026, from $6.6 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $11.9 million in Q1 2022 to a low of $21542.0 in Q2 2025.
• A 5-year average of $5.3 million and a median of $5.3 million in 2023 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2023 — Accumulated Expenses slumped 99.81% — and 2024, when it surged 23139.69%.
• Tracing SABS's Accumulated Expenses over 5 years: stood at $9.9 million in 2022, then plunged by 65.72% to $3.4 million in 2023, then soared by 60.96% to $5.5 million in 2024, then advanced by 20.3% to $6.6 million in 2025, then fell by 18.19% to $5.4 million in 2026.
• The last three Accumulated Expenses figures came in at $5.4 million (Q1 2026), $6.6 million (Q4 2025), and $3.7 million (Q3 2025), per Business Quant data.